Minerva Neurosciences, Inc. Securities Litigation

If you purchased a significant amount of shares of Minerva Neurosciences, Inc (NASDAQ: NERV), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Minerva Neurosciences, Inc
Date Filed:December 8th, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:May 15th, 2017
Class End Date:November 30th, 2020

According to the Complaint, Minerva Neurosciences, Inc. purports to be a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous diseases. The Company's lead product candidate is roluperidone, in development for the treatment of negative symptoms in patients with schizophrenia.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Minerva Neurosciences, Inc

 
First Identified Complaint

Nathan McCoy, et al. v. Minerva Neurosciences, Inc., et al.

Date Filed:December 8th, 2020
Class Period Start:May 15th, 2017
Class Period End:November 30th, 2020
First Identified Complaint Filings
#Document TitleFiling Date